Talk:Fenofibrate: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
imported>David E. Volk
(Just stick it in)
 
Line 9: Line 9:
Howard
Howard
[[User:Howard C. Berkowitz|Howard C. Berkowitz]] 23:55, 27 May 2008 (CDT)
[[User:Howard C. Berkowitz|Howard C. Berkowitz]] 23:55, 27 May 2008 (CDT)
Just start a new paragraph and write about it. If you point me to some thiazolidinediones in particular I can make a chemical structure drawing for you. [[User:David E. Volk|David E. Volk]] 08:45, 28 May 2008 (CDT)

Latest revision as of 07:45, 28 May 2008

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
To learn how to update the categories for this article, see here. To update categories, edit the metadata template.
 Definition Antilipemic medication which reduces both cholesterol and triglycerides in the blood. [d] [e]
Checklist and Archives
 Workgroup categories Health Sciences and Chemistry [Categories OK]
 Subgroup category:  Biochemistry
 Talk Archive none  English language variant American English

Synergistic use of PPARs for different subreceptors?

Both for personal use and research interest, I've been following some of the literature in the combined use of thiazolidinediones and fibrates. As you probably know, there seem to be some synergies in lowering cardiovascular risk, perhaps also with the fibrate potentiating the TZD role in decreasing insulin resistance by lowering circulating FFA.

Where might such a discussion go?

Howard Howard C. Berkowitz 23:55, 27 May 2008 (CDT)

Just start a new paragraph and write about it. If you point me to some thiazolidinediones in particular I can make a chemical structure drawing for you. David E. Volk 08:45, 28 May 2008 (CDT)